[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623256":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":53,"collaborators":57,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":26,"enrollmentInfo":68,"targetDuration":26,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":83,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"German University in Cairo","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"L-Arginine Arm","ACTIVE_COMPARATOR","Patients in this arm will be administered 6 gm L-arginine per day",[13],"Drug: L-Arginine Powder",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Arm","PLACEBO_COMPARATOR","Patients in this arm will take 6 gm placebo per day",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","L-Arginine Powder","L-arginine 3 gm sachets are used twice daily",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","2 sachets of placebo are administered per day",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Sara Araby, Msc","CONTACT","+201008662223","sara.araby96@gmail.com",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Mohamed Solayman, PhD","+201005882550","mohamed.solayman@guc.edu.eg",[42],{"facility":43,"status":26,"city":44,"state":26,"zip":26,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":26},"Ain Shams University","Cairo","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],31.24967,30.06263,{"lat":51,"lon":50},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Sara Araby","Msc.",[58],{"name":43,"class":6},"100623256","phase-2-effect-of-add-on-l-arginine-therapy-on-heart-failure-patients-100623256",false,"NCT07394270","Effect of Add-on L-Arginine Therapy on Heart Failure Patients","Effect of Add-on L-Arginine Therapy on Clinical Outcome of Heart Failure Patients: A Randomized- Controlled Trial","Inclusion Criteria:\n\n* Patients with EF \\\u003C40%\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2\n* Stable patients\n* Capable and willing to provide written consent\n\nExclusion Criteria:\n\n* Patients with implantable cardioverter-defibrillator\n* Pregnant or lactating fmeales\n* Patients with a history of sensitivity to L-Arginine or any of the excipients\n* Acute heart failure patients\n* Patients use L-arginine supplementation.\n* Patients with active herpes disease","ALL","19 Years",{"count":69,"type":70},200,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","Heart failure is considered one of the greatest challenges globally. There are various treatment strategies for heart failure. L-Arginine is an amino acid that was found to have beneficial effect on vasculature. This study aims to study the benefits and side effects of using L-arginine on the patients with ejection fraction \\\u003C40%",[76],"Heart Failure",[78,79,80,81,82],"Heart failure","Drug repurposing","L-Arginine","Add-on therapy","HFrEF","NOT_YET_RECRUITING","2026-02-01",{"date":86,"type":87},"2026-02-06","ACTUAL",{"date":89,"type":70},"2026-02",{"date":91,"type":70},"2027-07",{"name":5,"class":6},1]